Methylsulfonylpyrazolyl oxadiazoles and thiadiazoles as potent, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Seo, H.J.[Seo, H.J.] | - |
dc.contributor.author | Kim, M.J.[ Kim, M.J.] | - |
dc.contributor.author | Song, K.-S.[ Song, K.-S.] | - |
dc.contributor.author | Lee, S.-H.[ Lee, S.-H.] | - |
dc.contributor.author | Jung, M.E.[ Jung, M.E.] | - |
dc.contributor.author | Kim, M.-S.[ Kim, M.-S.] | - |
dc.contributor.author | Park, H.-J.[Park, H.-J.] | - |
dc.contributor.author | Yoo, J.[Yoo, J.] | - |
dc.contributor.author | Chang, C.-H.[ Chang, C.-H.] | - |
dc.contributor.author | Kim, J.[ Kim, J.] | - |
dc.contributor.author | Lee, J.[ Lee, J.] | - |
dc.date.accessioned | 2021-08-07T08:45:39Z | - |
dc.date.available | 2021-08-07T08:45:39Z | - |
dc.date.created | 2017-01-12 | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 1756-8919 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/79532 | - |
dc.description.abstract | Background: Since the cannabinoid receptor 1 (CB1) antagonist SR141716 (rimonabant) was previously reported to modulate food intake, CB1 antagonism has been considered as a new therapeutic target for the treatment of obesity. Discussion: In the present study, biarylpyrazole analogues based on a sulfur-containing pyrazole core coupled with 1,3,4-oxadiazole and 1,3,4-thiadiazole were synthesized and assayed for rat CB1 receptor binding affinity. Results: The structure-activity relationship studies to optimize pyrazole substituents as well as 1,3,4-oxadiazole or 1,3,4-thiadiazole rings led to four novel CB1 antagonists with IC50 values of approximately 1 nM for the rat CB1 receptor binding. Among these derivatives, we identified trifluoromethylcyclobutyl analogues 19e and 19l as promising precandidates for the development as anti-obesity agents. © 2009 Future Science Ltd. | - |
dc.subject | 1,3,4 oxadiazole derivative | - |
dc.subject | 1,3,4 thiadiazole derivative | - |
dc.subject | 2 [1 (2 chlorophenyl) 5 (4 chlorophenyl) 4 (methylsulfonyl) 1H pyrazol 3 yl] 5 [1 (trifluoromethyl)cyclobutyl] 1,3,4 thiadiazole | - |
dc.subject | 2 [5 (4 bromophenyl) 1 (2 chlorophenyl) 4 (methylsulfonyl) 1H pyrazol 3 yl] 5 [1 (trifluoromethyl)cyclobutyl]1,3,4 thiadiazole | - |
dc.subject | cannabinoid 1 receptor | - |
dc.subject | cannabinoid receptor antagonist | - |
dc.subject | unclassified drug | - |
dc.subject | animal cell | - |
dc.subject | animal experiment | - |
dc.subject | animal tissue | - |
dc.subject | article | - |
dc.subject | binding affinity | - |
dc.subject | controlled study | - |
dc.subject | drug bioavailability | - |
dc.subject | drug potency | - |
dc.subject | drug receptor binding | - |
dc.subject | drug selectivity | - |
dc.subject | drug synthesis | - |
dc.subject | IC 50 | - |
dc.subject | male | - |
dc.subject | nonhuman | - |
dc.subject | obesity | - |
dc.subject | oxidation | - |
dc.subject | priority journal | - |
dc.subject | rat | - |
dc.subject | structure activity relation | - |
dc.subject | Administration, Oral | - |
dc.subject | Animals | - |
dc.subject | Anti-Obesity Agents | - |
dc.subject | Binding Sites | - |
dc.subject | Biological Availability | - |
dc.subject | Computer Simulation | - |
dc.subject | Humans | - |
dc.subject | Mice | - |
dc.subject | Obesity | - |
dc.subject | Oxadiazoles | - |
dc.subject | Pyrazoles | - |
dc.subject | Rats | - |
dc.subject | Receptor, Cannabinoid, CB1 | - |
dc.subject | Structure-Activity Relationship | - |
dc.subject | Thiadiazoles | - |
dc.title | Methylsulfonylpyrazolyl oxadiazoles and thiadiazoles as potent, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, H.-J.[Park, H.-J.] | - |
dc.contributor.affiliatedAuthor | Yoo, J.[Yoo, J.] | - |
dc.identifier.doi | 10.4155/fmc.09.64 | - |
dc.identifier.scopusid | 2-s2.0-71749115522 | - |
dc.identifier.bibliographicCitation | Future Medicinal Chemistry, v.1, no.5, pp.947 - 967 | - |
dc.relation.isPartOf | Future Medicinal Chemistry | - |
dc.citation.title | Future Medicinal Chemistry | - |
dc.citation.volume | 1 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 947 | - |
dc.citation.endPage | 967 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREAsamsunglib@skku.edu
COPYRIGHT © 2021 SUNGKYUNKWAN UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.